Press Release

Organovo Announces Fiscal First-Quarter 2017 Results; Company Affirms Full-Year Fiscal 2017 and Long-Range Outlook

August 4, 2016 at 4:11 PM EDT

SAN DIEGO, Aug. 04, 2016 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NYSE MKT:ONVO) (“Organovo”), a three-dimensional biology company focused on delivering scientific and medical breakthroughs using its 3D bioprinting technology, today reported financial results for the fiscal first quarter of 2017 and affirmed its full-year fiscal 2017 and long-range outlook.  Net loss was $8.8 million, or $0.09 per share, for the fiscal first quarter of 2017, as compared to $8.5 million, or $0.10 per share, for the fiscal first quarter of 2016.

Organovo reported fiscal first-quarter total revenue of $0.9 million, which consisted largely of product and service revenue(1).  Total revenue increased 191 percent versus the comparable period of fiscal 2016 and 63 percent versus the fiscal fourth quarter of 2016.  Collaborations revenue(2), which primarily represents revenue from the Company’s research agreements with L’Oreal USA and Merck & Co., increased by $0.2 million from the year-ago period.

“We’re off to a strong start in fiscal 2017, nearly tripling our total revenue year-over-year in the first quarter and affirming our guidance across the board,” said Keith Murphy, CEO, Organovo.  “We continue to see solid adoption of our tissue research services, with an increase in new customers across the healthcare and biotechnology space signing agreements during the last few months.  We’ve also recently added two global Top 25 pharma customers, bringing our total to seven with this important and influential group, and are benefiting from a high percentage of repeat orders from our established customer base.  Many of our new customers now work with us under master service agreements, rather than signing up for just a single order or transaction.  We believe this framework supports repeat business and fosters our ability to become a standard part of customers’ toolkits for their drug discovery workflow.”   

Murphy continued, “We’re on track to commercialize our second tissue, the kidney proximal tubule, at the end of September.  We’re pleased with the momentum of our early access program for kidney tissue research services, having recently signed our first customer orders, with significant interest from additional biopharmaceutical companies to study the effects of drug exposure using our kidney model.  Kidney is a natural expansion of our preclinical solutions portfolio, showcasing the power and versatility of our technology platform.”

Murphy concluded, “Our long-term plan is sustained by reaching attractive and growing markets with critical unmet needs, extending our position as first mover in the 3D bioprinting space, and capitalizing on our technology leadership to grow our product and service offerings.” 

Organovo Business Highlights


  • Product and service revenue was $0.7 million, up 222 percent from the prior-year period, largely driven by an increase in customer contracts for the Company’s tissue research services. 
  • Collaborations revenue totaled $0.2 million, primarily supported by a milestone achievement from the Company’s agreement with Merck & Co. to develop multiple custom tissue models.         

Operating Expenses

  • Cost of revenues was $0.2 million, reflecting the Company’s total expenses related to manufacturing and delivering its product and service revenues. 
  • Research and development costs grew 7 percent year-over-year to $4.4 million, driven by increased employee related costs and lab supplies.
  • Selling, general and administrative expenses increased 9 percent from the prior-year period to $5.1 million, primarily due to higher employee related costs and non-cash share-based compensation expense.

Liquidity & Capital Resources

  • The Company ended the fiscal first quarter with a cash and cash equivalents balance of $53.5 million.  Organovo’s net cash utilization(3) during the period was $8.6 million
  • Working capital was $52.0 million to end the fiscal first quarter compared to $81.8 million in the prior-year quarter.  

Fiscal-Year 2017 Outlook

The Company affirmed its full-year fiscal 2017 outlook for total revenue, net cash utilization and initiation of commercial contracting for its kidney tissue product.  The Company continues to expect: 

  • Total revenue of between $4 million and $6 million for fiscal-year 2017.  Fiscal 2016 total revenue was $1.5 million
  • Net cash utilization of between $32.5 million and $36.5 million for fiscal-year 2017.  The Company had a cash and cash equivalents balance of $62.1 million for its fiscal year ended March 31, 2016.
  • Initiation of commercial contracting for its kidney tissue product in the calendar third quarter of 2016.
  Fiscal-Year 2017 Outlook
(June 2016)
Fiscal-Year 2017 Outlook
(August 2016)
Fiscal-Year 2017 Total
$4 million - $6 million Affirmed
Net Cash Utilization $32.5 million - $36.5 million Affirmed
Initiation of Commercial
   Contracting for Kidney Tissue  
Calendar Third Quarter
of 2016

Long-Range Outlook

The Company affirmed its long-range outlook for potential revenue from its liver tissue product.  The Company continues to expect:

  • As it penetrates the toxicology market, Organovo’s exVive3DTM Human Liver Tissue and service will grow into the tens of millions in annual revenue, and has $100 million+ revenue potential in the future (inside of a total addressable market of over $1 billion). 

Definitions & Supplemental Financial Measures

(1) Product and service revenue includes tissue research service agreements and product sales, including product sales from the Company’s wholly-owned subsidiary, Samsara Sciences Inc.
(2) Collaboration revenue consists of license and collaboration agreements that contain multiple elements, which may include non-refundable up-front fees, payments for reimbursement of third-party research costs, payments for ongoing research, payments associated with achieving specific development milestones and royalties based on specified percentages of net product sales, if any.
(3) In addition to disclosing financial results that are determined in accordance with U.S. GAAP, the Company provides net cash utilization as a supplemental measure to help investors evaluate the Company’s fundamental operational performance.  The Company defines net cash utilization as the change in the amount of cash and cash equivalents at the beginning of the reporting period as compared to the end of the reporting period, excluding financing activities (which would include proceeds from the sale of common stock and the exercise of warrants and stock options).  Net cash utilization is an operational measure that should be considered in addition to our results prepared in accordance with U.S. GAAP.  This operational measure should not be considered as a substitute for, or superior to, U.S. GAAP results.  The Company believes net cash utilization is a relevant and useful operational measure because it provides information regarding our cash utilization rate.    Management uses net cash utilization to manage the business, including in preparing its annual operating budget, financial projections and compensation plans.  The Company believes that net cash utilization is also useful to investors because similar measures are frequently used by securities analysts, investors and other interested parties in their evaluation of companies in similar industries.  However, there is no standardized measurement of net cash utilization, and net cash utilization as the Company presents it may not be comparable with similarly titled operational measures used by other companies.  Due to these limitations, the Company’s management does not view net cash utilization in isolation but also uses other measurements, such as cash used in operating activities and revenues to measure operating performance. 

Conference Call Information
As previously announced, the Company will host a conference call to discuss its results at 5:00 p.m. ET on Thursday, August 4, 2016.  Callers should dial (888) 317-6003 (U.S. only) or (412) 317-6061 (from outside the U.S.) to access the call.  The conference call ID is 2415344.  The conference call will also be simultaneously webcast on Organovo’s Investor Relations webpage at  A replay of the conference call will be available beginning Thursday, August 4, 2016 through Thursday, August 11, 2016 at Organovo’s Investor Relations webpage.  Callers can also dial (877) 344-7529 (U.S. only) or (412) 317-0088, Access Code 2415344, for an audio replay of the conference call.

About Organovo Holdings, Inc.

Organovo designs and creates functional, three-dimensional human tissues for use in medical research and therapeutic applications.  The Company develops 3D human tissue models through internal development and in collaboration with pharmaceutical, academic and other partners.  Organovo's 3D human tissues have the potential to accelerate the drug discovery process, enabling treatments to be developed faster and at lower cost.  The Company’s initial product is the exVive3DTM Human Liver Tissue for use in toxicology and other preclinical drug testing.  Additional products are in development, with the anticipated release of the exVive3D Human Kidney Tissue scheduled for the third quarter of calendar year 2016.  The Company also actively conducts early research on specific tissues for therapeutic use in direct surgical applications.  In addition to numerous scientific publications, the Company's technology has been featured in The Wall Street Journal, Time Magazine, The Economist, Forbes, and numerous other media outlets.  Organovo is changing the shape of life science research and transforming medical care.  Learn more at        

Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995.  Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties.  The factors that could cause the Company's actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products and services based on its technology; the expected benefits and efficacy of the Company's products, services and technology; the market acceptance of the Company's products and services; the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies; the Company's ability to successfully complete the contracts and recognize the revenue represented by the contracts included in its previously reported total contract bookings and secure additional contracted collaborative relationships.  These and other factors are identified and described in more detail in the Company's filings with the SEC, including its Annual Report on Form 10-K filed with the SEC on June 9, 2016.  You should not place undue reliance on these forward-looking statements, which speak only as of the date that they were made.  These cautionary statements should be considered with any written or oral forward-looking statements that the Company may issue in the future.  Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to reflect actual results, later events or circumstances or to reflect the occurrence of unanticipated events. 

 Organovo Holdings, Inc.   
 Unaudited Condensed Consolidated Statements of Operations  
 (in thousands except share and per share data)   
           Three Months Ended     Three Months Ended   
          June 30, 2016   June 30, 2015  
    Products and services $   674     $   209    
  Collaborations     213         14    
  Grants     4         83    
Total Revenues      891         306    
  Cost of revenues     168         -     
  Research and development expenses     4,444         4,142    
  Selling, general, and administrative expenses       5,056         4,622    
Loss from Operations      (8,777 )       (8,458 )  
Other Income (Expense)         
  Change in fair value of warrant liabilities     (5 )       (38 )  
  Interest income     37         8    
Total Other Income (Expense)      32         (30 )  
Income Tax Expense      (22 )       (3 )  
Net Loss  $   (8,767 )   $   (8,491 )  
Net loss per common share-basic and diluted $   (0.09 )   $   (0.10 )  
Weighted average shares used in computing net          
  loss per common share-basic and diluted     92,391,964         82,993,966    


 Organovo Holdings, Inc. 
Condensed Consolidated Balance Sheets
 (in thousands except for share data) 
        June 30, 2016   March 31, 2016  
         Unaudited    Audited  
Current Assets           
    Cash and cash equivalents       53,538         62,091    
  Accounts receivable       103         259    
  Inventory, net       512         334    
  Prepaid expenses and other current assets       1,028         968    
Total current assets       55,181         63,652    
Fixed assets, net       3,456         3,711    
Restricted cash       79         79    
Other assets, net       131         134    
Total assets       58,847         67,576    
Liabilities and Stockholders’ Equity           
Current Liabilities           
  Accounts payable       481         787    
  Accrued expenses       1,715         2,450    
  Deferred rent       140         139    
  Deferred revenue       791         1,110    
  Warrant liabilities       9         4    
Total current liabilities       3,136         4,490    
Deferred rent, net of current portion       868         905    
Total liabilities       4,004         5,395    
Commitments and contingencies           
Stockholders’ Equity           
  Common stock, $0.001 par value; 150,000,000 shares authorized,
92,389,730 and 92,391,989 shares issued and outstanding at
June 30, 2016 and March 31, 2016, respectively  
      92         92    
  Additional paid-in capital       224,388         222,959    
  Accumulated deficit       (169,637 )       (160,870 )  
Total stockholders’ equity       54,843         62,181    
Total Liabilities and Stockholders’ Equity        58,847         67,576    


 Organovo Holdings, Inc.   
Unaudited Condensed Consolidated Statements of Cash Flows (in thousands)  
           Three Months Ended     Three Months Ended   
          June 30, 2016   June 30, 2015  
Cash Flows From Operating Activities         
    Net loss $   (8,767 )   $   (8,491 )  
  Adjustments to reconcile net loss to net cash used in operating activities:          
      Depreciation and amortization     251         135    
    Change in fair value of warrant liabilities     5         38    
    Stock-based compensation     1,429         1,780    
    Amortization of warrants issued for services     -          (95 )  
    Increase (decrease) in cash resulting from changes in:        
        Accounts receivable     156         (132 )  
      Inventory     (178 )       (3 )  
      Prepaid expenses and other assets     (41 )       256    
      Accounts payable     (306 )       (357 )  
      Accrued expenses     (735 )       (611 )  
      Deferred rent     (36 )       (8 )  
      Deferred revenue     (319 )       1,193    
Net cash used in operating activities      (8,541 )       (6,295 )  
Cash Flows From Investing Activities        
  Purchases of fixed assets     (12 )       (1,135 )  
Net cash used in investing activities      (12 )       (1,135 )  
Cash Flows From Financing Activities        
  Proceeds from issuance of common stock and exercise of warrants, net     -          43,214    
  Proceeds from exercise of stock options     -          77    
  Principal payments on capital lease obligations     -          (3 )  
Net cash provided by financing activities      -          43,288    
Net Increase (Decrease) in Cash and Cash Equivalents      (8,553 )       35,858    
Cash and Cash Equivalents at Beginning of Period      62,091         50,142    
Cash and Cash Equivalents at End of Period  $   53,538     $   86,000    
Supplemental Disclosure of Cash Flow Information:         
Interest $   -      $   -     
Income Taxes $   (22 )   $   (3 )  


Investor Contact:

Steve Kunszabo
Organovo Holdings, Inc.
+1 (858) 224-1092

Press Contact:

Jessica YinglingLittle Dog Communications
+1 (858) 480-2411

Primary Logo

Organovo, Inc.
© 2022 Organovo Holdings, Inc. 6275 Nancy Ridge Drive, Suite 110 San Diego, CA 92121